GlassScriptPhysician profile
Amanda Armas
NPI 1184458663
$2,851.94
in general payments reported to CMS, 2019-2025
28 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $304 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $343.01 | 2024-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Sequel Med Tech, LLC | $308.34 | 2025 | Twiist |
| Medtronic, INC. | $264.34 | 2024-2025 | Minimed 780g |
| Corcept Therapeutics | $260.26 | 2024-2025 | Korlym |
| Lilly USA, LLC | $227.79 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $227.65 | 2025 | Omnipod |
| Novo Nordisk INC | $181.96 | 2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $158.00 | 2025 | Evenity, Repatha |
| Recordati_rare_diseases_inc. | $140.05 | 2024-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $112.03 | 2024-2025 | |
| Rgh Enterprises LLC | $78.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.22 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $51.95 | 2024-2025 | Crysvita |
| Genzyme Corporation | $47.10 | 2025 | |
| Dexcom, INC. | $43.35 | 2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $37.57 | 2025 | Vykat Xr |
| Tandem Diabetes Care, INC. | $35.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ionis Pharmaceuticals, INC. | $34.71 | 2025 | Tryngolza |
| Alexion Pharmaceuticals, INC. | $34.49 | 2025 | Strensiq |
| Alnylam Pharmaceuticals INC. | $33.58 | 2025 | Givlaari |
| Acella Pharmaceuticals, LLC | $33.18 | 2025 | NP Thyroid 60 |
| Neurocrine Biosciences, INC. | $28.73 | 2025 | |
| Antares Pharma, INC. | $24.23 | 2024 | Xyosted |
| Madrigal Pharmaceuticals | $20.30 | 2025 | Rezdiffra |
| Ascensia Diabetes Care US INC. | $17.48 | 2025 | |
| Cequr Corporation | $15.20 | 2025 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $14.27 | 2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Armas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.